Scotiabank analyst raised Bristol-Myers Squibb’s price target to $60, citing a catalyst-rich 2026. FDA granted Priority Review to Opdivo combined with AVD chemotherapy for Hodgkin Lymphoma. Opdivo-AVD regimen significantly improved progression-free survival in patients. Bristol-Myers Squibb is a biopharmaceutical company. Some believe AI stocks offer greater upside potential than BMY. No disclosures in the article.

Read more at Yahoo Finance: Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth